Laurel Wealth Advisors Inc. Sells 419 Shares of Pfizer Inc. (NYSE:PFE)

Share on StockTwits

Laurel Wealth Advisors Inc. lessened its holdings in Pfizer Inc. (NYSE:PFE) by 0.6% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 66,225 shares of the biopharmaceutical company’s stock after selling 419 shares during the quarter. Laurel Wealth Advisors Inc.’s holdings in Pfizer were worth $2,869,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also made changes to their positions in the business. Nomura Asset Management Co. Ltd. lifted its holdings in shares of Pfizer by 3.5% in the 2nd quarter. Nomura Asset Management Co. Ltd. now owns 1,287,595 shares of the biopharmaceutical company’s stock worth $55,778,000 after buying an additional 43,921 shares during the period. Qtron Investments LLC lifted its holdings in shares of Pfizer by 65.9% in the 2nd quarter. Qtron Investments LLC now owns 25,147 shares of the biopharmaceutical company’s stock worth $1,089,000 after buying an additional 9,989 shares during the period. Tiemann Investment Advisors LLC lifted its stake in shares of Pfizer by 2.1% during the 2nd quarter. Tiemann Investment Advisors LLC now owns 14,980 shares of the biopharmaceutical company’s stock worth $649,000 after purchasing an additional 302 shares during the last quarter. Blackhawk Capital Partners LLC. lifted its stake in shares of Pfizer by 3.4% during the 2nd quarter. Blackhawk Capital Partners LLC. now owns 48,472 shares of the biopharmaceutical company’s stock worth $2,100,000 after purchasing an additional 1,598 shares during the last quarter. Finally, ETRADE Capital Management LLC lifted its stake in shares of Pfizer by 14.4% during the 2nd quarter. ETRADE Capital Management LLC now owns 110,894 shares of the biopharmaceutical company’s stock worth $4,804,000 after purchasing an additional 13,974 shares during the last quarter. 71.84% of the stock is currently owned by institutional investors.

NYSE:PFE traded down $0.02 during mid-day trading on Friday, hitting $37.26. 139,833 shares of the company’s stock traded hands, compared to its average volume of 21,779,912. The company has a fifty day moving average of $36.81 and a 200 day moving average of $40.81. Pfizer Inc. has a twelve month low of $33.97 and a twelve month high of $46.47. The company has a market capitalization of $207.47 billion, a P/E ratio of 12.41, a P/E/G ratio of 2.97 and a beta of 0.65. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.21 and a current ratio of 1.47.

Pfizer (NYSE:PFE) last announced its earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.75 by $0.05. Pfizer had a return on equity of 28.10% and a net margin of 23.58%. The company had revenue of $13.26 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period in the prior year, the company posted $0.77 EPS. The firm’s quarterly revenue was down 1.5% compared to the same quarter last year. On average, research analysts expect that Pfizer Inc. will post 2.81 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 3rd. Investors of record on Friday, August 2nd were given a dividend of $0.36 per share. This represents a $1.44 annualized dividend and a yield of 3.86%. The ex-dividend date was Thursday, August 1st. Pfizer’s dividend payout ratio is currently 48.00%.

A number of equities research analysts recently weighed in on the company. Morgan Stanley decreased their price objective on Pfizer from $40.00 to $38.00 and set an “equal weight” rating for the company in a research note on Tuesday, August 27th. Goldman Sachs Group restated a “buy” rating and set a $49.00 price objective on shares of Pfizer in a research note on Monday, June 17th. Credit Suisse Group restated a “neutral” rating on shares of Pfizer in a research note on Monday, August 12th. Bank of America cut Pfizer from a “buy” rating to a “neutral” rating in a research note on Tuesday, July 30th. Finally, UBS Group restated a “neutral” rating and set a $43.00 price objective on shares of Pfizer in a research note on Monday, August 5th. Fifteen research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Pfizer has a consensus rating of “Hold” and a consensus target price of $45.88.

In other news, Director Scott Gottlieb acquired 3,000 shares of the business’s stock in a transaction dated Friday, August 23rd. The shares were acquired at an average cost of $34.72 per share, with a total value of $104,160.00. Following the completion of the acquisition, the director now owns 3,000 shares of the company’s stock, valued at $104,160. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Alexander R. Mackenzie sold 30,000 shares of the stock in a transaction dated Thursday, June 20th. The shares were sold at an average price of $44.00, for a total value of $1,320,000.00. Following the completion of the transaction, the insider now directly owns 80,094 shares in the company, valued at $3,524,136. The disclosure for this sale can be found here. Corporate insiders own 0.09% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Story: Why do companies pay special dividends?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Insider Buying: NAOS Small Cap Opportunities Company Ltd  Insider Acquires A$66,200.00 in Stock
Insider Buying: NAOS Small Cap Opportunities Company Ltd Insider Acquires A$66,200.00 in Stock
Insider Selling: Och-Ziff Capital Management Group Inc  Insider Sells $62,014.14 in Stock
Insider Selling: Och-Ziff Capital Management Group Inc Insider Sells $62,014.14 in Stock
Godaddy Inc  Director Sells $55,870.50 in Stock
Godaddy Inc Director Sells $55,870.50 in Stock
Insider Selling: Wayfair Inc  CFO Sells $61,843.64 in Stock
Insider Selling: Wayfair Inc CFO Sells $61,843.64 in Stock
S&W Seed  Posts  Earnings Results, Misses Expectations By $0.55 EPS
S&W Seed Posts Earnings Results, Misses Expectations By $0.55 EPS
Tailored Brands Inc  Director Buys $69,600.00 in Stock
Tailored Brands Inc Director Buys $69,600.00 in Stock


© 2006-2019 Ticker Report